Nieprawidłowa dieta jest głównym czynnikiem niekorzystnie wpływającym na stan zdrowia i wystąpienie chorób przewlekłych, w tym chorób układu krążenia. Samo włączenie pojedynczego suplementu, bez odpowiednich korekt nieprawidłowych zwyczajów żywieniowych, może nie przynieść oczekiwanych efektów. Niedobór lub nadmiar określonych składników pokarmowych może bowiem niwelować korzystny wpływ przyjmowanego suplementu.

Omega-3 PUFA supplementation in the prevention of cardiovascular diseases

Abstract

Many researchers report that omega-3 PUFAs have a positive influence on the proper functioning of a body and the health status. They can be beneficial during pregnancy, supporting normal fetal development. They can also reduce inflammation, including rheumatoid arthritis and asthma. Some studies suggest that omega-3 PUFAs can help to reduce the risk of neurodegenerative diseases and diabetes. However, the most extensively studied effects of these acids relate to their application in the primary and secondary prevention of cardiovascular diseases.

Piśmiennictwo

1. Włodarek D. Znaczenie kwasów tłuszczowych omega-3 dla zdrowia. Klin Pediatr 2016;24:7039-44.

2. Kłosiewicz-Latoszek L. Znaczenie kwasów tłuszczowych omega-3 w profilaktyce chorób sercowo-naczyniowych. Żyw Człow Metab 2002;XXIX:78-86.

3. Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation, Geneva, 28 January-1 February 2002. World Health Organ Tech Rep Ser 2003;916:i-viii.

4. Simopolous AP. Summary of the NATO advanced research workshop on dietary omega-3 and omega-6 fatty acids: biological effects and nutritional essentiality. J Nut 1989;119:521-8.

5. International Society for the Study of Fatty Acids and Lipids. Report of the Sub-Committee on Recommendations for Intake of Polyunsaturated Fatty Acids in Healthy Adults, June 2004, http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf (dostęp: 1.08.2017).

6. De Deckere EA, Korver O, Verschuren PM, et al. Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin. Eur J Clin Nutr 1998;52:749-53.

7. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 2010;8:1461.

8. Perk J, De Backer G, Gohlke H, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.

9. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.

10. Reiner Z, Catapano AL, de Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.

11. Vannice G, Rasmussen H. Position of the Academy of Nutrition and Dietetics: dietary fatty acids for healthy adults. J Acad Nutr Diet 2014;114:136-53.

12. Kris-Etherton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106: 2747-57.

13. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.

14. Jarosz M. Normy żywienia dla populacji polskiej – nowelizacja. Warszawa: Wydawnictwo Instytutu Żywności i Żywienia, 2012.

15. Hooper L, Thompson RL, Harrison RA, et al. Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;18:CD003177.

16. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.

17. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.

18. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135-40.

19. Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009;206:535-9.

20. Sasaki J, Yokoyama M, Matsuzaki M, et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). J Atheroscler Thromb 2012;19:194-204.

21. Kromhout D, Giltay EJ, Geleijnse JM, et al. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26.

22. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9.

23. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341:c6273.

24. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.

25. Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-8.

26. Bonds DE, Harrington M, Worrall BB, et al. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014;174:763-71.

27. Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686-94.

28. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33.

29. Wen YT, Dai JH2, Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2014;24:470-5.

30. Chen Q, Cheng LQ, Xiao TH, et al. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011;25:259-65.

31. Casula M, Soranna D, Catapano AL, et al. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl 2013;14:243-51.

32. Tajuddin N, Shaikh A, Hassan A. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes Metab Syndr Obes 2016;9:109-18.

33. Chen GC, Yang J, Eggersdorfer M, et al. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis. Sci Rep 2016;6:28165.

34. Zhao LG, Sun JW, Yang Y, et al. Fish consumption and all-cause mortality: a meta-analysis of cohort studies. Eur J Clin Nutr 2016;70:155-61.

35. Li YH, Zhou CH, Pei HJ, et al. Fish consumption and incidence of heart failure: a meta-analysis of prospective cohort studies. Chin Med J (Engl) 2013;126:942-8.

36. Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012;15: 725-37.

37. Larsson SC, Orsini N. Fish consumption and the risk of stroke: a dose-response meta-analysis. Stroke 2011;42:3621-3.

38. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation 2017;135(15):e867-e884.

39. Papanikolaou Y, Brooks J, Reider C, et al. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J 2014;13:31.

Do góry